German cancer specialists in immuno-oncology deal

16 March 2017
2019_biotech_test_vial_discovery_big

Cancer immunotherapy company Provecs Medical GmbH and oncology pharma Medac GmbH have announced a collaboration to take forward a product for urinary bladder cancer and other solid cancers.

The privately-held German partners aim to develop, manufacture and market Provec’s cancer immunotherapy lead product Immunalon. They have not disclosed financial details of the deal.

“We are seeking partners for the development of Immunalon in other solid cancer indications with high medical need and a lack of standard therapies.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology